Shares of McKesson Co. (NYSE:MCK) have received an average rating of “Hold” from the fifteen research firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $133.99.

Several research firms have issued reports on MCK. Zacks Investment Research upgraded shares of McKesson from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Wolfe Research assumed coverage on shares of McKesson in a report on Tuesday, April 2nd. They issued an “outperform” rating on the stock. UBS Group assumed coverage on shares of McKesson in a report on Thursday, January 17th. They issued a “neutral” rating and a $134.00 price target on the stock. ValuEngine raised shares of McKesson from a “strong sell” rating to a “sell” rating in a report on Monday, February 4th. Finally, Barclays reissued a “hold” rating and issued a $130.00 price target on shares of McKesson in a report on Friday, February 1st.

Several large investors have recently modified their holdings of the company. Quadrant Capital Group LLC grew its holdings in shares of McKesson by 5.7% during the 4th quarter. Quadrant Capital Group LLC now owns 1,784 shares of the company’s stock valued at $190,000 after purchasing an additional 96 shares during the last quarter. Courier Capital LLC grew its holdings in shares of McKesson by 4.0% during the 4th quarter. Courier Capital LLC now owns 2,614 shares of the company’s stock valued at $289,000 after purchasing an additional 100 shares during the last quarter. Certified Advisory Corp grew its holdings in shares of McKesson by 12.6% during the 4th quarter. Certified Advisory Corp now owns 1,089 shares of the company’s stock valued at $120,000 after purchasing an additional 122 shares during the last quarter. Valeo Financial Advisors LLC grew its holdings in shares of McKesson by 25.9% during the 1st quarter. Valeo Financial Advisors LLC now owns 627 shares of the company’s stock valued at $73,000 after purchasing an additional 129 shares during the last quarter. Finally, Old North State Trust LLC grew its holdings in shares of McKesson by 53.3% during the 4th quarter. Old North State Trust LLC now owns 391 shares of the company’s stock valued at $43,000 after purchasing an additional 136 shares during the last quarter. 86.60% of the stock is currently owned by hedge funds and other institutional investors.

NYSE MCK traded up $2.73 on Tuesday, hitting $115.20. The stock had a trading volume of 936,825 shares, compared to its average volume of 1,532,069. McKesson has a 52-week low of $106.11 and a 52-week high of $160.84. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.02 and a quick ratio of 0.57. The stock has a market capitalization of $21.82 billion, a PE ratio of 9.13, a P/E/G ratio of 1.15 and a beta of 1.24.

McKesson (NYSE:MCK) last posted its earnings results on Thursday, January 31st. The company reported $3.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.18 by $0.22. McKesson had a negative net margin of 0.15% and a positive return on equity of 27.83%. The business had revenue of $56.21 billion for the quarter, compared to analysts’ expectations of $55.27 billion. During the same period in the prior year, the company posted $3.41 EPS. On average, research analysts anticipate that McKesson will post 13.55 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend was Thursday, February 28th. McKesson’s payout ratio is 12.36%.

About McKesson

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Featured Article: Benefits of owning preferred stock

Analyst Recommendations for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.